HomeAI · summaries
Storia in 4 fonti
This Top 4% Biotech Is Plunging; Why Analysts Aren't Sweating
Spyre Therapeutics took a hit Wednesday after its experimental rheumatoid arthritis treatment failed to pass muster in midstage testing.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Spyre tumbles as immune drug misses mark in rheumatoid arthritis
The results erased more than $1 billion in market value and raised questions about how impactful drugs that block the TL1A protein might be against the condition.
- ·
endpoints.news
Spyre drops rheumatoid arthritis hopes for anti-TL1A drug after modest Phase 2 data
Spyre deprioritizes anti-TL1A drug SPY072 in RA after Phase 2 misses its bar; shares dip 12% as SKYLINE UC data nears in September.
